BioCorRx Pharmaceuticals Awarded New Patent for Novel Compound to Treat Pain, Depression & Schizophrenia
BioCorRx Inc. recently announced its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has been granted a new patent by the United States Patent and Trademark Office (USPTO).
The USPTO has issued US Patent No. 11,793,801 titled Treatment of Pain and Neurological Conditions. The patent is directed toward the use of a compound and composition and/or dosage form for treating pain, depression, and schizophrenia.
Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., and President, and Chairman of BioCorRx Pharmaceuticals Inc., commented “The patented invention may offer a novel approach to reducing the severity of withdrawal symptoms for opioid use disorder compared to current standards of care.”
Opioid withdrawal syndrome can be characterized as a flu-like illness, subjectively severe but objectively mild. It may occur if someone is physically dependent on opioids and then abruptly stops or reduces their use of opioids. Symptoms may include dysphoria, insomnia, pupillary dilation, piloerection, yawning, muscle aches, lacrimation, rhinorrhea, nausea, fever, sweating, vomiting, and diarrhea.
Depression is a major depressive disorder. It is a common and serious medical illness which can affect how someone feels, acts, and how a person thinks. An estimated 6.7% of adults are affected by depression annually and 16.6% of people will experience depression at some point in their life.
Schizophrenia is a serious brain disorder marked by positive symptoms (hallucinations and delusions, disorganized speech and thoughts, and agitated or movements). It is a mental illness that affects how a person thinks, feels, and behaves. Schizophrenia affects approximately 1% of Americans.
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company focused on researching and developing unique approaches to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx’s proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts, and personal support from behavioral experts, please visit www.uncraverx.com for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical-stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com.
Total Page Views: 1707
